N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KYM, Philip R, MENET, Christel Jeanne Marie, DE BLIECK, Ann, PIZZONERO, Mathieu Rafael, GOSMINI, Romain Luc Marie, SWIFT, Elizabeth C, WANG, Xueqing, LEFRANCOIS, Jean-Michel, BOCK, Xavier Marie, JANSEN, Koen Karel, MERAYO, Nuria Merayo, PALISSE, Adeline Marie Elise, HOUSSEMAN, Christopher Gaetan, DE LEMOS, Elsa, AKKARI, Rhalid, DESROY, Nicolas, CLAES, Pieter Isabelle Roger, VAN DER PLAS, Steven Emiel, PATEL, Sachin V, COWART, Marlon D, SHRESTHA, Anurupa, BROWN, Brian S, NEWSOME, Gregory John Robert, DUTHION, Béranger, GFESSER, Gregory A, MAMMOLITI, Oscar, JI, Jianguo, ALVEY, Luke Jonathan
Format:	Patent
Sprache:	eng ; lit
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).